Univariate analysis
| Risk factor . | . | End points . | ||
|---|---|---|---|---|
| RFS, 3 y . | Relapse, 3 y . | NRM (d 100/3 y) . | ||
| Probability/Cumulative incidence (%)/HR (CI) | ||||
| Donor | ||||
| HLA-identical related | 56 | 16 | 12/28 | |
| Unrelated | 59 | 11 | 13/30 | |
| HLA ≠ | 27 | 21 | 36/52 | |
| P | .11 | .57 | .11 | |
| FAB classification | ||||
| RA/RARS | 65 | 5/1.05-151 | 15/30 | |
| RAEB | 32 | 34/8.5 (2.2-33) | 21/30 | |
| RAEB-T/tAML | 18 | 32/8.6 (1.7-43) | 10/51 | |
| Other | 67 | 0/NC5-152 | 17/33 | |
| P | .08 | .002 | .86 | |
| Cytogenetic risk | ||||
| Good | 60 | 9/1.05-151 | 14/31 | |
| Intermediate | 56 | 13/2.1 (0.4-11) | 13/31 | |
| Poor | 40 | 26/5.2 (1.5-18) | 21/34 | |
| P | .11 | .03 | .75 | |
| Etiology | ||||
| De novo | 62/1.05-151 | 11/1.05-151 | 13/27 | |
| Chemo/radiotherapy | 12/2.8 (1.4-5.7) | 41/5.4 (1.7-17) | 29/48 | |
| Predisposing disease | 50/1.3 (0.6-2.9) | 6/0.8 (0.1-6.4) | 18/44 | |
| P | .03 | .03 | .32 | |
| IPSS risk | ||||
| Low | 80 | 0/NC5-152 | 13/20 | |
| Intermediate-1 | 64 | 6/0.2 (0.0-0.6) | 9/30 | |
| Intermediate-2 | 40 | 29/0.7 (0.2-2.7) | 25/31 | |
| High | 29 | 42/1.05-151 | 0/29 | |
| P | .14 | .009 | .83 | |
| Acute GVHD | ||||
| Grades 0-I | 60 | 19 | 10/20 | |
| Grades II-IV | 51 | 12 | 18/37 | |
| P | .05 | .56 | .006 | |
| Risk factor . | . | End points . | ||
|---|---|---|---|---|
| RFS, 3 y . | Relapse, 3 y . | NRM (d 100/3 y) . | ||
| Probability/Cumulative incidence (%)/HR (CI) | ||||
| Donor | ||||
| HLA-identical related | 56 | 16 | 12/28 | |
| Unrelated | 59 | 11 | 13/30 | |
| HLA ≠ | 27 | 21 | 36/52 | |
| P | .11 | .57 | .11 | |
| FAB classification | ||||
| RA/RARS | 65 | 5/1.05-151 | 15/30 | |
| RAEB | 32 | 34/8.5 (2.2-33) | 21/30 | |
| RAEB-T/tAML | 18 | 32/8.6 (1.7-43) | 10/51 | |
| Other | 67 | 0/NC5-152 | 17/33 | |
| P | .08 | .002 | .86 | |
| Cytogenetic risk | ||||
| Good | 60 | 9/1.05-151 | 14/31 | |
| Intermediate | 56 | 13/2.1 (0.4-11) | 13/31 | |
| Poor | 40 | 26/5.2 (1.5-18) | 21/34 | |
| P | .11 | .03 | .75 | |
| Etiology | ||||
| De novo | 62/1.05-151 | 11/1.05-151 | 13/27 | |
| Chemo/radiotherapy | 12/2.8 (1.4-5.7) | 41/5.4 (1.7-17) | 29/48 | |
| Predisposing disease | 50/1.3 (0.6-2.9) | 6/0.8 (0.1-6.4) | 18/44 | |
| P | .03 | .03 | .32 | |
| IPSS risk | ||||
| Low | 80 | 0/NC5-152 | 13/20 | |
| Intermediate-1 | 64 | 6/0.2 (0.0-0.6) | 9/30 | |
| Intermediate-2 | 40 | 29/0.7 (0.2-2.7) | 25/31 | |
| High | 29 | 42/1.05-151 | 0/29 | |
| P | .14 | .009 | .83 | |
| Acute GVHD | ||||
| Grades 0-I | 60 | 19 | 10/20 | |
| Grades II-IV | 51 | 12 | 18/37 | |
| P | .05 | .56 | .006 | |
Other factors considered included donor and patient CMV serology, patient age, donor age, disease duration (≤ 6 mo; 6-12 mo; 12-24 mo; > 24 mo), busulfan levels (< 800; 800-900; > 900 ng/mL), donor/patient gender combination, source of hemopoietic stem cells (marrow versus PBSCs), cell dose. None of these was significant for any end point.
Reference for calculation of hazard ratio (HR).
Cannot be computed.